The virus is still ahead of our response
In the forests and fractured provinces of northeastern Congo, a rare strain of Ebola is rewriting the record books in the most harrowing way — spreading faster in its opening weeks than any outbreak before it, including the catastrophic West African epidemic that claimed more than 11,000 lives a decade ago. With no approved vaccine, no proven treatment, and a health system already hollowed out by conflict and poverty, the Bundibugyo virus is outrunning the very infrastructure meant to stop it. This is not merely a medical emergency unfolding in isolation; it is a crisis born at the intersection of disease, displacement, and a world that has begun to look away from its most vulnerable places.
- Cases are doubling every 28 days — a pace that has already surpassed the early trajectory of the deadliest Ebola outbreak in history, with 1,759 confirmed cases and 600 deaths in under two months.
- The Bundibugyo strain carries no approved vaccine and no proven cure, leaving health workers to fight an accelerating fire with no extinguisher, while a 34% fatality rate means one in three infected people does not survive.
- Contact tracing — the backbone of outbreak control — is running at 82%, far short of the 95% threshold needed, as armed conflict in Ituri and South Kivu makes it physically dangerous to follow the virus into the communities where it hides.
- Two experimental treatments entered trials on July 2nd, offering a fragile thread of hope, but officials warn that $1.4 billion is urgently needed and that funding cuts and geopolitical neglect are actively widening the gap between the virus and the response.
- Treatment centers are operating at 90% capacity across four provinces, laboratory testing has scaled dramatically, yet every gain is being absorbed by a transmission rate that the response infrastructure simply cannot match.
On a Thursday in July, African health officials delivered an assessment that stopped the room: the Ebola outbreak tearing through the Democratic Republic of Congo had become the fastest-growing on record. The World Health Organization confirmed 600 deaths among 1,759 cases since the outbreak was declared in mid-May — but it was the trajectory, not just the toll, that made the numbers truly alarming.
The comparison was laid out plainly by Wessam Mankoula of the Africa CDC. The 2013–2016 West African epidemic — still the deadliest Ebola outbreak in history — had reached 994 cases in its first six weeks. The current DRC outbreak had already hit 1,596 in the same window. Cases were doubling every 28 days. "Unfortunately, the virus is still ahead of our response," Mankoula told reporters.
The culprit is Bundibugyo, a rare Ebola strain with no approved vaccine and no proven treatment. It took hold in Ituri province — a mineral-rich, conflict-scarred corner of northeastern DRC — and has since spread to three other provinces. The case fatality rate stands at 34 percent. Of those infected, 285 have recovered; hundreds of suspected cases remain under investigation.
The response is straining from every direction. Twenty-two treatment centers with roughly 700 beds are running at 90% capacity. Contact tracing covers 82% of known exposures — meaningful progress, but still short of the 95% threshold health officials say is needed to truly bend the curve. Laboratory capacity has surged from 30 daily tests in Kinshasa to over 2,000 across decentralized provincial labs, yet even that expansion cannot keep pace with transmission.
On July 2nd, trials began for two experimental therapies — the monoclonal antibody MBP134 and the antiviral remdesivir — tested alone and in combination. They represent the clearest hope for changing the outbreak's direction. But Mankoula was direct: the full response will require $1.4 billion, and donors must move faster.
The virus is not spreading into a stable landscape. The DRC was already one of the world's most complex humanitarian emergencies — millions displaced by conflict, healthcare systems hollowed out, basic services out of reach for vast populations. South Kivu, one of the affected provinces, has seen active clashes between Congolese forces and the Rwanda-backed M23 group. Recent cuts to international humanitarian funding have made an already impossible situation worse. Ebola has not arrived in a place of fragility. It has arrived in a place that was already breaking.
On Thursday, African health officials delivered a stark assessment: the Ebola outbreak spreading through the Democratic Republic of Congo is moving faster than any recorded before it. The World Health Organization had just confirmed 600 deaths among 1,759 documented cases since the outbreak was declared in mid-May. The numbers alone were alarming enough. But what made them truly unsettling was the trajectory.
Wessam Mankoula, who leads emergency preparedness for the Africa Centres for Disease Control and Prevention, laid out the comparison plainly. The deadliest Ebola outbreak on record—the 2013-2016 West African epidemic—had accumulated 994 cases in its first six weeks. The current outbreak in the DRC had already reached 1,596 cases in the same timeframe. The virus was not just spreading; it was accelerating. Cases were doubling every 28 days, and the response infrastructure was falling behind. "Unfortunately, the virus is still ahead of our response," Mankoula told reporters. "It's moving faster than deploying the resources to control the situation."
The outbreak is caused by Bundibugyo, a rare strain of Ebola with no approved vaccine and no proven treatment. It spreads through close contact with infected people and their bodily fluids—a transmission pattern that becomes exponentially more dangerous in regions already fractured by conflict and poverty. The virus took hold in Ituri province, a mineral-rich area in northeastern DRC that has long been destabilized by armed groups. From there it has spread to three other provinces. The case fatality rate stands at 34 percent—meaning roughly one in three infected people dies. So far, 285 patients have recovered, while 304 suspected cases remain under investigation.
The response is straining under multiple pressures. Anne Ancia, the WHO's representative in the DRC, noted that population movements, ongoing insecurity, and the weakness of the health system itself are all working against containment efforts. The DRC has assembled 22 treatment centers with around 700 beds, with another 300 beds planned. These facilities are running at roughly 90 percent capacity. More than 10,000 contacts of infected people are being tracked, but the follow-up rate sits at 82 percent—well below the 95 percent threshold that health officials believe is necessary to truly control the outbreak. Laboratory testing capacity has improved dramatically, scaling from 30 tests per day in the capital Kinshasa to over 2,000 across decentralized labs in the affected provinces. Yet even these gains are not enough to match the speed of transmission.
On July 2, trials began for two experimental treatments: a monoclonal antibody called MBP134 and the antiviral drug remdesivir, tested both separately and in combination. These represent the only real hope for shifting the trajectory. But hope alone will not stop the outbreak. Mankoula said the total response effort would require $1.4 billion. He called on donors and international partners to accelerate the release of those funds. "We need to surge our response, and surging our response means financial resources, human resources," he said.
The broader context makes the crisis even more dire. The DRC was already one of the world's most complex humanitarian emergencies before Ebola arrived. Millions of people were already displaced by conflict, facing hunger, weak healthcare systems, and limited access to basic services. One of the affected provinces, South Kivu, has been the site of clashes between Congolese armed forces and the Rwanda-backed M23 armed group. Tom Fletcher, head of UN humanitarian operations, noted that recent cuts to humanitarian funding have made an already impossible situation worse. The virus is not spreading into a stable, well-resourced environment. It is spreading into a landscape of fragility, where the systems needed to contain it are already stretched to breaking.
Notable Quotes
This is the fastest growing Ebola outbreak ever, not only among the previous Bundibugyo outbreaks, but all the different viruses that are causing Ebola.— Wessam Mankoula, Africa Centres for Disease Control and Prevention
DRC is one of the world's most complex humanitarian crises. Recent cuts in humanitarian funding have made the response even harder.— Tom Fletcher, head of UN humanitarian operations
The Hearth Conversation Another angle on the story
Why is this outbreak moving so much faster than previous ones?
The Bundibugyo strain has no vaccine and no approved treatment, which means there's no medical intervention to slow transmission. But speed also comes from context—the DRC's health system was already fragile, insecurity keeps people moving unpredictably, and the virus had time to spread before anyone detected it.
The 34 percent fatality rate—is that high for Ebola?
It's significant. You're looking at roughly one death for every three infections. That's not the highest Ebola has ever been, but it's high enough that every case matters enormously. And when cases are doubling every 28 days, the absolute numbers become catastrophic very quickly.
They mention contact tracing at 82 percent when 95 percent is needed. What's the difference between those numbers in practical terms?
That 13-point gap means roughly one in seven infected contacts is slipping through the net. In an outbreak doubling every month, those missed contacts become the seeds for the next wave. It's the difference between containment and loss of control.
The $1.4 billion figure—is that realistic to raise?
It's what the response actually needs. Whether donors will provide it is another question entirely. The DRC is already one of the world's most complex humanitarian crises, and funding for those situations is chronically underfunded. Recent cuts have made things worse.
What does it mean that the trials started on July 2?
It means there's finally a chance to test whether these drugs actually work. But trials take time, and the outbreak isn't waiting. Even if one of these treatments proves effective, scaling it up to reach thousands of patients across a conflict-affected region is a massive logistical challenge.